Analysis of IL-10, IL-4 and TNF-α polymorphisms in drug-induced liver injury (DILI) and its outcome

Journal of Hepatology

Volumn 49, Issue 1, 2008, Pages 107-114

  Pachkoria, Ketevan ^a   Lucena, M Isabel ^a   Crespo, Esperanza ^b   Ruiz Cabello, Francisco ^c   Lopez Ortega, Susana ^d   Fernandez, Ma Carmen ^e   Romero Gomez, Manuel ^f   Madrazo, Ana ^f   Durán, Jose Antonio ^g   de Dios, Ana Malcon ^g   Borraz, Yolanda ^a   Navarro, Jose Maria ^h   Andrade, Raúl J ^d  

^a Facultad de Medicina   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d Grupo de Estudio para Las Hepatopatias Asociadas a Medicamentos   (Spain)

^e Servicio de Farmacología Clínica   (Spain)

^f HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^g Servicio de Farmacología Clínica   (Spain)

^h H Costa del Sol   (Spain)

Author keywords

Cytokines; Drugs; Genetic susceptibility; Hepatotoxicity; Interleukin 10; Interleukin 4; Outcome; Single nucleotide polymorphism; Tumor Necrosis factor alpha

Indexed keywords

ALPRAZOLAM; AMOXICILLIN PLUS CLAVULANIC ACID; EBROTIDINE; FLUTAMIDE; INTERLEUKIN 10; INTERLEUKIN 4; ISONIAZID; NIMESULIDE; PARACETAMOL; PAROXETINE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BIOASSAY; CASE CONTROL STUDY; CHOLESTASIS; CHOLESTATIC HEPATITIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EOSINOPHIL COUNT; FEMALE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; LIVER CELL DAMAGE; LIVER INJURY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TEA;

EID: 44649186853     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.03.017     Document Type: Article

References (44)

1. Temple R.J., and Himmel M.H. Safety of newly approved drugs: implications for prescribing. JAMA 287 (2002) 2273-2275
2. Kaplowitz N. Mechanisms of liver cell injury. J Hepatol 32 (2000) 39-47
3. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4 (2005) 489-499
4. Aithal G.P., Ramsay L., Daly A.K., Sonchit N., Leathart J.B., Alexander G., et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39 (2004) 1430-1440
5. Bourdi M., Masubuchi Y., Reilly T.P., Amouzadeh H.R., Martin J.L., George J.W., et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 35 (2002) 289-298
6. Eskdale J., Gallagher G., Verweij C.L., Keijsers V., Westendorp R.G., and Huizinga T.W. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 95 (1998) 9465-9470
7. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174 (1991) 915-924
8. Louis H., Van Laethem J.L., Wu W., Quertinmont E., Degraef C., Van den Berg K., et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology 28 (1998) 1607-1615
9. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., and Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24 (1997) 1-8
10. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793
11. Howard M., and Paul W.E. Interleukins for B lymphocytes. Lymphokine Res 1 (1982) 1-4
12. Rosenwasser L.J., Klemm D.J., Dresback J.K., Inamura H., Mascali J.J., Klinnert M., et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 25 (1995) 74-78
13. Kawashima T., Noguchi E., Arinami T., Yamakawa-Kobayashi K., Nakagawa H., Otsuka F., et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet 35 (1998) 502-504
14. Wanidworanun C., and Strober W. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 151 (1993) 6853-6861
15. D'Alfonso S., and Richiardi P.M. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 39 (1994) 150-154
16. Fowler E.V., Eri R., Hume G., Johnstone S., Pandeya N., Lincoln D., et al. TNFalpha and IL10 SNPs act together to predict disease behaviour in Crohn's disease. J Med Genet 42 (2005) 523-528
17. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., Shorthouse C., and Powell E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30 (1999) 526-530
18. Andrade R.J., Lucena M.I., Alonso A., Garcia-Cortes M., Garcia-Ruiz E., Benitez R., et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39 (2004) 1603-1612
19. Danan G., and Benichou C. Causality assessment of adverse reactions to drugs - I A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46 (1993) 1323-1330
20. Benichou C. Criteria of drug-induced liver disorders report of an international consensus meeting. J Hepatol 11 (1990) 272-276
21. World Health Organisation Collaborating Center for drugs statistics methodology. Anatomical Therapeutic Chemical (ATC) classification index including defined daily dose (DDDs) for plane substances (2005). Oslo: World Health Organisation Collaborating Center for drugs statistics methodology.
22. Andrade R.J., Lucena M.I., Fernandez M.C., Pelaez G., Pachkoria K., Garcia-Ruiz E., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-521
23. Pachkoria K., Lucena M.I., Ruiz-Cabello F., Crespo E., Cabello M.R., and Andrade R.J. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 150 (2007) 808-815
24. Pelletier R., Pravica V., Perrey C., Xia D., Ferguson R.M., Hutchinson I., et al. Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 70 (2000) 674-680
25. Tambur A.R., Yaniv I., Stein J., Lapidot M., Shabtai E., Kfir B., et al. Cytokine gene polymorphism in patients with graft-versus-host disease. Transplant Proc 33 (2001) 502-503
26. Watkins P.B., and Seeff L.B. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 43 (2006) 618-631
27. Lang C., Meier Y., Stieger B., Beuers U., Lang T., Kerb R., et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 17 (2007) 47-60
28. Alonso R., Suarez A., Castro P., Lacave A.J., and Gutierrez C. Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res 15 (2005) 53-60
29. Scarpelli D., Cardellini M., Andreozzi F., Laratta E., Hribal M.L., Marini M.A., et al. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes 55 (2006) 1529-1533
30. Costeas P.A., Koumas L., Koumouli A., Kyriakou-Giantsiou A., and Papaloizou A. Cytokine polymorphism frequencies in the Greek Cypriot population. Eur J Immunogenet 30 (2003) 341-343
31. Kamangar F., Abnet C.C., Hutchinson A.A., Newschaffer C.J., Helzlsouer K., Shugart Y.Y., et al. Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland). Cancer Causes Control 17 (2006) 117-125
32. Karjalainen J., Hulkkonen J., Nieminen M.M., Huhtala H., Aromaa A., Klaukka T., et al. Interleukin-10 gene promoter region polymorphism is associated with eosinophil count and circulating Immnunoglobulin E in adult asthma. Clin Exp Allergy 33 (2003) 78-83
33. Hutchings A., Guay-Woodford L., Thomas J.M., Young C.J., Purcell W.M., Pravica V., et al. Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transpl 6 (2002) 69-77
34. Warle M.C., Farhan A., Metselaar H.J., Hop W.C., Perrey C., Zondervan P.E., et al. Are cytokine gene polymorphisms related to in vitro cytokine production profiles?. Liver Transpl 9 (2003) 170-181
35. Persico M., Capasso M., Persico E., Masarone M., Renzo A., Spano D., et al. Interleukin-10 -1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol 45 (2006) 779-785
36. Goedecke V., Crane A.M., Jaakkola E., Kaluza W., Laiho K., Weeks D.E., et al. Interleukin 10 polymorphisms in ankylosing spondylitis. Genes Immun 4 (2003) 74-76
37. Bjornsson E., Nordlinder H., and Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 44 (2006) 791-797
38. Bjornsson E., Kalaitzakis E., and Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 25 (2007) 1411-1421
39. Lampinen M., Ronnblom A., Amin K., Kristjansson G., Rorsman F., Sangfelt P., et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 54 (2005) 1714-1720
40. Betwaite P.B.H.L.J., Yeong M.L., and Thornton A. Effect of tumor associated tissue eosinophilia on survival of women with stage IB carcinoma of the uterine cervix. J Clin Pathol 46 (1993) 1016-1020
41. Pulitano C., Sitia G., Aldrighetti L., Finazzi R., Arru M., Catena M., et al. Reduced severity of liver ischemia/reperfusion injury following hepatic resection in humans is associated with enhanced intrahepatic expression of Th2 cytokines. Hepatol Res 36 (2006) 20-26
42. Yumoto E., Higashi T., Nouso K., Nakatsukasa H., Fujiwara K., Hanafusa T., et al. Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J Gastroenterol Hepatol 17 (2002) 285-294
43. Tsukamoto H., Takei Y., McClain C.J., Joshi-Barve S., Hill D., Schmidt J., et al. How is the liver primed or sensitized for alcoholic liver disease?. Alcohol Clin Exp Res 25 (2001) 171-181
44. Forns X., and Bukh J. The molecular biology of hepatitis C virus genotypes and quasispecies. Clin Liver Dis 3 (1999) 693-716